Deal of the Day — today's pharmacy picks
Kisqali 600mg Tablet

Kisqali 600mg Tablet

Prescription requiredRx Required

Salt Composition: Ribociclib

Expiry Date: 01/2028

Special offer

Enquire

Inclusive of all taxes

▼

21 Tablets in Strip

About The Product

​Breast Cancer​

Kisqali 600mg Tablet contain active ingredient Ribociclib. It is a targeted therapy anticancer drug prescribed to treat metastatic breast cancer. It works by blocking the action of specific proteins to slow down the growth of cancer cells and progression of disease. It can be used alone or in combination with other medicines. Ribociclib should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.


Uses

  • Metastatic breast cancer

Side Effects

Kisqali 600mg Tablet can cause multiple side effects, most of which are mild to moderate and often temporary. Patients are advised to inform their healthcare provider immediately if symptoms stays for prolonged period of time.    

Common side effects include:

  • Infection
  • Anemia
  • Decreased appetite
  • Vomiting
  • Headache
  • Low blood platelets
  • Decreased potassium level in blood
  • Decreased white blood cell count
  • Dizziness
  • Vertigo
  • Fainting
  • Increased lacrimation
  • Breathlessness
  • Cough
  • Itching
  • Abnormal liver enzyme
  • Rash
  • Nausea
  • Constipation
  • Fatigue
  • Diarrhea
  • Decreased white blood cell count
  • Hair loss

How To Use

  • Take Kisqali 600mg Tablet in exact dose as prescribed by the doctor. The typical dose of this capsule varies with age and overall health factor of the patient. It can be taken with or without food but at a fixed time each day to get better results.
  • Ribociclib 600mg should be swallowed as a whole with water without crushing, chewing, or opening the capsule. Don't miss a dose or overdose the medicine.


How It Works

Kisqali 600mg Tablet contain active ingredient Ribociclib. It is a targeted therapy anticancer drug that works by blocking the action of proteins (kinases) which are responsible for the growth and division of cells.

Results in slows the growth of cancer cells and eventually kills them.

Safety Advice

Alcohol
Avoid the consumption of alcohol while taking Kisqali 600mg Tablet, as alcohol can decrease the effectiveness of the medicine as well as worsen the symptoms.
Pregnancy
Do not take Kisqali 600mg Tablet without consulting the doctor in case of pregnancy, as it can be unsafe to take it during this period.
Breast Feeding
Breastfeeding women should discuss the potential risks and benefits of the Kisqali 600mg Tablet with their healthcare provider before starting treatment.
Driving
Kisqali 600mg Tablet may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving.
Kidney
Share your medical history with the doctor before starting the Kisqali 600mg Tablet. Do not take it without consulting a doctor if you have any kidney related issue.
Liver
Share your medical history with the doctor before starting the Kisqali 600mg Tablet. Do not take it without consulting a doctor if you have any liver related issue.

FAQs

It is used in the treatment of metastatic breast cancer.

It belongs to a group of cancer-fighting medications known as antineoplastics.

References

  1. Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S. A., ... & Jerusalem, G. (2020). Overall survival with ribociclib plus fulvestrant in advanced breast cancer. New England Journal of medicine , 382 (6), 514-524.

    PubMed

  2. Slamon, D., Lipatov, O., Nowecki, Z., McAndrew, N., Kukielka-Budny, B., Stroyakovskiy, D., ... & Hortobagyi, G. (2024). Ribociclib plus endocrine therapy in early breast cancer. New England Journal of Medicine , 390 (12), 1080-1091.

    PubMed

  3. Im, S. A., Lu, Y. S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., ... & Tripathy, D. (2019). Overall survival with ribociclib plus endocrine therapy in breast cancer. New England journal of medicine , 381 (4), 307-316.

    nejm.org

  4. Tripathy, D., Bardia, A., & Sellers, W. R. (2017). Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clinical Cancer Research , 23 (13), 3251-3262.

    PubMed

  5. Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., ... & O’Shaughnessy, J. (2016). Ribociclib as first-line therapy for HR-positive, advanced breast cancer. New England journal of medicine , 375 (18), 1738-1748.

    nejm.org

Certified Content

Written By
Venika Choudhary

Venika Choudhary

Medical Content Writer @ Magicine Pharma

Reviewed By
Dr. Aditya Sarin

Dr. Aditya Sarin

MBBS, MD - General Medicine, DrNB - Medical Oncology | 11 Years Experience

Check Our Editorial Policy

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026